Microsoft word - boa - egypt_10-9-2012

Chairpersons: Laila Moussa - Kamal El-Ghamrawy - Zekry Khalid - Mohsen Barsoum Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapaƟnib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. Effect of osteoporosis in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC NSABP B-38: DefiniƟve analysis of paƟent outcome from a randomized trial comparing dose-dense (DD) AC followed by paclitaxel (P) plus gemcitabine (G) with DD AC followed by P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparƟcle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or RTOG 9804: A prospecƟve randomized trial for “good risk” ductal carcinoma in situ (DCIS), comparing radiaƟon (RT) to New insights into the risk of breast cancer in childhood cancer survivors treated with chest radiation: A report from the Childhood Cancer Survivor Study (CCSS) and the Women's Environmental Cancer and Radiation Epidemiology (WECARE) Chairpersons: Shawky Al-Hadad - Yousri Gouda - Sohir Ismail - Ashraf Barakat LUX-lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Phase III trial of concurrent thoracic radiotherapy (TRT) with either the first cycle or the third cycle of cisplatin and etoposide chemotherapy to determine the optimal timing of TRT for limited-disease small cell lung cancer. TAILOR: Phase III trial comparison of erlotinib versus docetaxel in the second-line treatment of wild type (wt) EGFR A randomized phase III trial of single agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. Is consolidation chemotherapy after concurrent chemoradiotherapy beneficial for locally advanced non-small cell lung cancer? A pooled analysis of the literature. Chairpersons: Omar Zaky - Omar Hekal - Atef Yousef - Samir Shehata Phase III randomized trial of definitive chemoradiotherapy (CRT) with FOLFOX or cisplatin and fluorouracil in esophageal cancer (EC): Final results of the PRODIGE 5/ACCORD 17 trial. A randomized controlled phase II study of theprophylactic effect of urea-based cream on the hand-foot skin reaction associated with sorafenib in advanced hepatocellular carcinoma. Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplaƟn (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II. A randomized, multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) with or without panitumumab in previously untreated advanced esophagogastric cancer (REAL3). : Ehsan El-Ghonemy - Kamal Hamd - Abbas Sarhan – Hanaa Atia METRIC: A phase III randomized, open-label study comparing trametinib (GSK1120212) to chemotherapy (CT) in CT-naive or pre-treated patients with advanced or metastatic BRAFV600E/k mutation-positive melanoma. Long-term follow-up results of EORTC 26951: A randomized phase III study on adjuvant PCV chemotherapy in anaplastic Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results Chairpersons: Ahmd El-Zawawy - Magda Mostafa – Mona Abo EL-Enin - Magda El-Mongy Interim analysis results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC). Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) paƟents (pts): Results of S9346 (INT-0162), an internaƟonal phase III trial. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. Final overall survival analysis results from the phase III, double-blind, randomized, multinational study of radium-223 chloride in the treatment of patients with castration-resistant prostate cancer (CRPC) with bone metastases (ALSYMPCA). Chairpersons: Nadia Mokhtar - Somia Ezzat - Hana Kohail Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). The prognostic importance of miRNA-21 in stage II colon cancer: A populaƟon-based study. Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC). EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Effects of prior bevacizumab (B) use on outcomes from the VELOUR study: A phase III study of aflibercept (Afl) and FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regimen. Chairpersons: Said El Noweiam - Moneir Abo Elella - Salah El-Mesidy DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in paƟents with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozanƟnib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. Chairpersons: Hossam Kamel - Faiza Hamouda - Hamdy El-Zawam - Hanan Hamed ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial. Dasatinib versus imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): DASISION 3-year R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL). Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the SƟL NHL1 study. Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX). PACE: A pivotal phase II trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or Chairpersons: Nier El-Ghamry - Mervat El-Nagar - Mohamed Abdeen – Amr Abe El-Aziz AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) combined with chemotherapy (CT) for platinum- resistant recurrent ovarian cancer (OC). Long-term follow-up of a randomized trial comparing conventional paclitaxel and carboplatin with dose-dense weekly paclitaxel and carboplatin in women with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer: JGOG A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). Sarcomas – Palliative Care – Cancer Prevention Chairpersons: Mostafa El-Serafi – Talat El Mokadim – Hany Akkosh Cluster-randomized trial of early palliative care for patients with metastatic cancer. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial. A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial. *Not endorsed by the official BOA program.

Source: http://www.egycs.org/files/BOA%20-%20Egypt_12-9-2012.pdf